Danish biotech boss after shelved Lilly project: "We have better molecules"

Eli Lilly has interrupted the development of an experimental diabetes drug licensed in from a subsidiary of Danish Nordic Bioscience. According to CEO in Nordic Bioscience, Morten Karsdal, there are better molecules to develop in the partnership.

Photo: Nordic Bioscience/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles